Reaction
Chondropathy reporting signals
As of the last recalculation, Chondropathy appears in 2,697 FAERS reports alongside 35 co-occurring drug terms. The strongest observed disproportionality signal is CAPTOPRIL (PRR 16.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Captopril | 20 | 16.2 | 16.2 |
| Leflunomide | 170 | 13.3 | 13.3 |
| Doxepin | 16 | 12.2 | 12.3 |
| Doxepin Hydrochloride | 19 | 11.7 | 11.7 |
| Felodipine Extended-Release Tablets | 13 | 8.8 | 8.9 |
| Felodipine | 13 | 8.8 | 8.9 |
| Adalimumab | 636 | 8.8 | 8.8 |
| Abatacept | 143 | 8.4 | 8.4 |
| Methotrexate | 360 | 7.5 | 7.5 |
| Etanercept | 479 | 7.3 | 7.3 |
| Amlodipine Besylate And Valsartan | 10 | 7.0 | 7.0 |
| Methotrexate Sodium | 378 | 6.8 | 6.8 |
| Nebivolol | 14 | 6.8 | 6.8 |
| Celecoxib | 111 | 6.7 | 6.7 |
| Tofacitinib | 153 | 6.7 | 6.7 |
| Hydroxychloroquine | 59 | 6.2 | 6.2 |
| Alendronate Sodium Tablet | 14 | 5.9 | 5.9 |
| Emtricitabine And Tenofovir Alafenamide | 8 | 5.5 | 5.5 |
| Infliximab | 137 | 5.0 | 5.1 |
| Ropinirole | 10 | 5.0 | 5.0 |
| Nebivolol Hydrochloride | 21 | 4.8 | 4.8 |
| Sulfasalazine | 47 | 4.7 | 4.7 |
| Upadacitinib | 45 | 4.3 | 4.3 |
| Golimumab | 40 | 3.6 | 3.6 |
| Interferon Beta-1A | 85 | 3.5 | 3.5 |
| Testosterone Cypionate | 4 | 3.5 | 3.5 |
| Teriparatide | 47 | 3.3 | 3.3 |
| Botulinum Toxin Type A | 5 | 3.1 | 3.1 |
| Asfotase Alfa | 4 | 3.1 | 3.1 |
| Ranitidine Hydrochloride | 19 | 2.7 | 2.7 |
| Certolizumab Pegol | 40 | 2.7 | 2.7 |
| Conjugated Estrogens And Medroxyprogesterone Acetate | 8 | 2.6 | 2.6 |
| Cariprazine | 3 | 2.5 | 2.5 |
| Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Alafenamide | 3 | 2.3 | 2.3 |
| Diroximel Fumarate | 3 | 1.9 | 1.9 |